Trexquant Investment LP Acquires 16,248 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Trexquant Investment LP raised its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 18.2% in the 4th quarter, Holdings Channel reports. The firm owned 105,528 shares of the company’s stock after purchasing an additional 16,248 shares during the quarter. Trexquant Investment LP’s holdings in Amphastar Pharmaceuticals were worth $3,918,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. increased its position in Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after purchasing an additional 398 shares during the period. Point72 DIFC Ltd grew its stake in Amphastar Pharmaceuticals by 85.9% in the third quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock valued at $192,000 after acquiring an additional 1,827 shares during the period. Weiss Asset Management LP bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $4,967,000. Wellington Management Group LLP acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $957,000. Finally, XTX Topco Ltd acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $674,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $26.61 on Friday. The firm has a market capitalization of $1.27 billion, a P/E ratio of 8.87, a P/E/G ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 52 week low of $25.89 and a 52 week high of $53.96. The stock has a 50 day moving average price of $30.24 and a two-hundred day moving average price of $39.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Insider Buying and Selling

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 27.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.